Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Inclusion Criteria: * Patients older than 18 years who require cataract surgery * Both genders * Provide informed consent * Normal Laboratory results Exclusion Criteria: * Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery * Patients with any trans-surgical complication * Patients with a cataract \>NC4, C4 or P4 classified with the system LOCS * Patients with any active corneal pathology * Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior surgery or NSAIDs 7 days before the surgery (except low-dose aspirin) * Patients with IOP \<5 or \>21 mmHg * Patients that have ocular pain, cellularity or flare at the moment of selection * Patients with ocular exfoliation, trauma or any inflammatory disease * Patients with diabetic retinopathy that need treatment or uncontrolled diabetes mellitus * Patients who are planning cataract surgery of the contralateral eye 14 days after surgery of the study eye * Patients with history of hypersensitivity or contraindication for any drug used in the study * Patients under anticoagulant treatment * Contact lens users * Pregnant patients, at risk of pregnancy or breastfeeding * Patients without birth control treatment * Patients with any active toxicomania (alcoholism, cigarette, cannabis or others) * Patients who had participated in any clinical trial in the last 90 days * Legal or mentally disabled patients who could not give informed consent * Patients who cannot comply with all study requirements